Compare · AXNX vs DXCM
AXNX vs DXCM
Side-by-side comparison of Axonex AI Group Limited (AXNX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- AXNX operates in Consumer Discretionary, while DXCM operates in Health Care - the two are in different parts of the market.
- DXCM is the larger of the two at $33.00B, about 5236.6x AXNX ($6.3M).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 2 for AXNX).
- DXCM has more recent analyst coverage (25 ratings vs 21 for AXNX).
- Company
- Axonex AI Group Limited
- DexCom Inc.
- Price
- -
- -
- Market cap
- $6.3M
- $33.00B
- 1M return
- -
- +6.10%
- 1Y return
- -
- +49.23%
- Industry
- Business Services
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2005
- News (4w)
- 2
- 9
- Recent ratings
- 21
- 25
Axonex AI Group Limited
Axonex AI Group Limited (formerly Mint Incorporation Limited) (NASDAQ: AXNX) is a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider. Through its subsidiary, Axonex AI Limited, and its majority owned subsidiary, Rice Robotics AGI Holding Limited, the Group delivers robot models and robotics solutions, including the FLOKI Minibot M1 and micro-insurance solutions purpose-built for commercial robots. The Group also maintains its established interior design and fit-out works business. Anchored by its ongoing transformation, Axonex AI is focused on AI and robotics as its main growth driving engine.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest AXNX
- Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split
- Axonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMO
- Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
- SEC Form 15-12G filed by Axonics Inc.
- SEC Form EFFECT filed by Axonics Inc.
- SEC Form 25-NSE filed by Axonics Inc.
- Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
Latest DXCM
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
- Dexcom Reports Third Quarter 2026 Financial Results
- EVP Chief People & Culture Off Stern Sadie sold $201,660 worth of shares (2,565 units at $78.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- EVP Chief Legal Compliance Off Brown Michael Jon sold $145,316 worth of shares (1,700 units at $85.48) as part of a pre-agreed trading plan (SEC Form 4)
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target